[Skip to Content]

Claim CME

Drug Development

Therapy for Early COVID-19A Critical Need

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA

Published Online: November 11, 2020

Viewpoint

Article Information and Disclosures

Peter S. Kim, MD¹;

Sarah W. Read, MD, MHS¹;

Anthony S. Fauci, MD²

Author Affiliations

¹Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
²National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Read article on JAMA Network

Review

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

James M. Sanders, PhD, PharmD; Marguerite L. Monogue, PharmD; Tomasz Z. Jodlowski, PharmD; James B. Cutrell, MD
Viewpoint

Ensuring Scientific Integrity and Public Confidence in the Search for Effective COVID-19 Treatment

Jesse L. Goodman, MD, MPH; Luciana Borio, MD
Original Investigation

Treatment With Hydroxychloroquine or Azithromycin and In-Hospital Mortality in Patients With COVID-19

Eli S. Rosenberg, PhD; Elizabeth M. Dufort, MD; Tomoko Udo, PhD; Larissa A. Wilberschied, MS; Jessica Kumar, DO; James Tesoriero, PhD; Patti Weinberg, PA; James Kirkwood, MPH; Alison Muse, MPH; Jack DeHovitz, MD; Debra S. Blog, MD; Brad Hutton, MPH; David R. Holtgrave, PhD; Howard A. Zucker, MD
Viewpoint

Monoclonal Antibodies for Prevention and Treatment of COVID-19

Mary Marovich, MD; John R. Mascola, MD; Myron S. Cohen, MD
Review

Coronavirus Disease 2019 (COVID-19)—Epidemiology, Diagnosis, and Treatment

W. Joost Wiersinga, MD, PhD; Andrew Rhodes, MD, PhD; Allen C. Cheng, MD, PhD; Sharon J. Peacock, PhD; Hallie C. Prescott, MD, MSc
Original Investigation

Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Shruti Gupta, MD, MPH; Wei Wang, PhD; Salim S. Hayek, MD; Lili Chan, MD, MSCR; Kusum S. Mathews, MD, MPH, MSCR; Michal L. Melamed, MD, MHS; Samantha K. Brenner, MD, MPH; Amanda Leonberg-Yoo, MD, MS; Edward J. Schenck, MD, MS; Jared Radbel, MD; Jochen Reiser, MD, PhD; Anip Bansal, MD; Anand Srivastava, MD, MPH; Yan Zhou, MD; Diana Finkel, DO; Adam Green, MD, MBA; Mary Mallappallil, MD; Anthony J. Faugno, MD; Jingjing Zhang, MD, PhD; Juan Carlos Q. Velez, MD; Shahzad Shaefi, MD, MPH; Chirag R. Parikh, MD, PhD; David M. Charytan, MD, MSc; Ambarish M. Athavale, MBBS, MD; Allon N. Friedman, MD; Roberta E. Redfern, PhD; Samuel A. P. Short, BA; Simon Correa, MD, MMSc; Kapil K. Pokharel, MBBS; Andrew J. Admon, MD, MPH, MSc; John P. Donnelly, PhD; Hayley B. Gershengorn, MD; David J. Douin, MD; Matthew W. Semler, MD; Miguel A. Hernán, MD, DrPH; David E. Leaf, MD, MMSc; STOP-COVID Investigators; Carl P. Walther; Samaya J. Anumudu; Justin Arunthamakun; Kathleen F. Kopecky; Gregory P. Milligan; Peter A. McCullough; Thuy-Duyen Nguyen; Shahzad Shaefi; Megan L. Krajewski; Sidharth Shankar; Ameeka Pannu; Juan D. Valencia; Sushrut S. Waikar; Zoe A. Kibbelaar; Ambarish M. Athavale; Peter Hart; Shristi Upadhyay; Ishaan Vohra; Ajiboye Oyintayo; Adam Green; Jean-Sebastien Rachoin; Christa A. Schorr; Lisa Shea; Daniel L. Edmonston; Christopher L. Mosher; Alexandre M. Shehata; Zaza Cohen; Valerie Allusson; Gabriela Bambrick-Santoyo; Noor ul aain Bhatti; Bijal Mehta; Aquino Williams; Samantha K. Brenner; Patricia Walters; Ronaldo C. Go; Keith M. Rose; Miguel A. Hernán; Rebecca Lisk; Amy M. Zhou; Ethan C. Kim; Lili Chan; Kusum S. Mathews; Steven G. Coca; Deena R. Altman; Aparna Saha; Howard Soh; Huei Hsun Wen; Sonali Bose; Emily A. Leven; Jing G. Wang; Gohar Mosoyan; Girish N. Nadkarni; Pattharawin Pattharanitima; Emily J. Gallagher; Allon N. Friedman; John Guirguis; Rajat Kapoor; Christopher Meshberger; Katherine J. Kelly; Chirag R. Parikh; Brian T. Garibaldi; Celia P. Corona-Villalobos; Yumeng Wen; Steven Menez; Rubab F. Malik; Carmen Elena Cervantes; Samir C. Gautam; Mary C. Mallappallil; Jie Ouyang; Sabu John; Ernie Yap; Yohannes Melaku; Ibrahim Mohamed; Siddhartha Bajracharya; Isha Puri; Mariah Thaxton; Jyotsna Bhattacharya; John Wagner; Leon Boudourakis; H. Bryant Nguyen; Afshin Ahoubim; Kianoush Kashani; Shahrzad Tehranian; Leslie F. Thomas; Dheeraj Reddy Sirganagari; Pramod K. Guru; Yan Zhou; Paul A. Bergl; Jesus Rodriguez; Jatan A. Shah; Mrigank S. Gupta; Princy N. Kumar; Deepa G. Lazarous; Seble G. Kassaye; Michal L. Melamed; Tanya S. Johns; Ryan Mocerino; Kalyan Prudhvi; Denzel Zhu; Rebecca V. Levy; Yorg Azzi; Molly Fisher; Milagros Yunes; Kaltrina Sedaliu; Ladan Golestaneh; Maureen Brogan; Neelja Kumar; Michael Chang; Jyotsana Thakkar; Ritesh Raichoudhury; Akshay Athreya; Mohamed Farag; Edward J. Schenck; Soo Jung Cho; Maria Plataki; Sergio L. Alvarez-Mulett; Luis G. Gomez-Escobar; Di Pan; Stefi Lee; Jamuna Krishnan; William Whalen; David Charytan; Ashley Macina; Sobaata Chaudhry; Benjamin Wu; Frank Modersitzki; Anand Srivastava; Alexander S. Leidner; Carlos Martinez; Jacqueline M. Kruser; Richard G. Wunderink; Alexander J. Hodakowski; Juan Carlos Q. Velez; Eboni G. Price-Haywood; Luis A. Matute-Trochez; Anna E. Hasty; Muner MB. Mohamed; Rupali S. Avasare; David Zonies; David E. Leaf; Shruti Gupta; Meghan E. Sise; Erik T. Newman; Samah Abu Omar; Kapil K. Pokharel; Shreyak Sharma; Harkarandeep Singh; Simon Correa; Tanveer Shaukat; Omer Kamal; Wei Wang; Heather Yang; Jeffery O. Boateng; Meghan Lee; Ian A. Strohbehn; Jiahua Li; Ariel L. Mueller; Roberta E. Redfern; Nicholas S. Cairl; Gabriel Naimy; Abeer Abu-Saif; Danyell Hall; Laura Bickley; Chris Rowan; Farah Madhani-Lovely; Vasil Peev; Jochen Reiser; John J. Byun; Andrew Vissing; Esha M. Kapania; Zoe Post; Nilam P. Patel; Joy-Marie Hermes; Anne K. Sutherland; Amee Patrawalla; Diana G. Finkel; Barbara A. Danek; Sowminya Arikapudi; Jeffrey M. Paer; Peter Cangialosi; Mark Liotta; Jared Radbel; Sonika Puri; Jag Sunderram; Matthew T. Scharf; Ayesha Ahmed; Ilya Berim; Jayanth S. Vatson; Shuchi Anand; Joseph E. Levitt; Pablo Garcia; Suzanne M. Boyle; Rui Song; Ali Arif; Jingjing Zhang; Sang Hoon Woo; Xiaoying Deng; Goni Katz-Greenberg; Katharine Senter; Moh’d A. Sharshir; Vadym V. Rusnak; Muhammad Imran Ali; Terri Peters; Kathy Hughes; Anip Bansal; Amber S. Podoll; Michel Chonchol; Sunita Sharma; Ellen L. Burnham; David J. Douin; Arash Rashidi; Rana Hejal; Eric Judd; Laura Latta; Ashita Tolwani; Timothy E. Albertson; Jason Y. Adams; Steven Y. Chang; Rebecca M. Beutler; Carl E. Schulze; Etienne Macedo; Harin Rhee; Kathleen D. Liu; Vasantha K. Jotwani; Jay L. Koyner; Chintan V. Shah; Vishal Jaikaransingh; Stephanie M. Toth-Manikowski; Min J. Joo; James P. Lash; Javier A. Neyra; Nourhan Chaaban; Madona Elias; Yahya Ahmad; Alfredo Iardino; Elizabeth H. Au; Jill H. Sharma; Marie Anne Sosa; Sabrina Taldone; Gabriel Contreras; David De La Zerda; Alessia Fornoni; Hayley B. Gershengorn; Salim S. Hayek; Pennelope Blakely; Hanna Berlin; Tariq U. Azam; Husam Shadid; Michael Pan; Patrick O’ Hayer; Chelsea Meloche; Rafey Feroze; Kishan J. Padalia; Abbas Bitar; Jeff Leya; John P. Donnelly; Andrew J. Admon; Jennifer E. Flythe; Matthew J. Tugman; Emily H. Chang; Brent R. Brown; Amanda K. Leonberg-Yoo; Ryan C. Spiardi; Todd A. Miano; Meaghan S. Roche; Charles R. Vasquez; Amar D. Bansal; Natalie C. Ernecoff; Sanjana Kapoor; Siddharth Verma; Huiwen Chen; Csaba P. Kovesdy; Miklos Z. Molnar; Ambreen Azhar; S. Susan Hedayati; Mridula V. Nadamuni; Shani Shastri; Duwayne L. Willett; Samuel A.P. Short; Amanda D. Renaghan; Kyle B. Enfield; Pavan K. Bhatraju; A. Bilal Malik; Matthew W. Semler; Anitha Vijayan; Christina Mariyam Joy; Tingting Li; Seth Goldberg; Patricia F. Kao; Greg L. Schumaker; Nitender Goyal; Anthony J. Faugno; Caroline M. Hsu; Asma Tariq; Leah Meyer; Ravi K. Kshirsagar; Aju Jose; Daniel E. Weiner; Marta Christov; Jennifer Griffiths; Sanjeev Gupta; Aromma Kapoor; Perry Wilson; Tanima Arora; Ugochukwu Ugwuowo

Read Article Claim CME

While coronavirus disease 2019 (COVID-19) is predominantly self-limited, up to 20% of symptomatic individuals will progress to severe or critical disease with clinical manifestations including pneumonia, acute respiratory distress syndrome, multiorgan system dysfunction, hypercoagulation, and hyperinflammatory manifestations. There have been more than 47 million cases of COVID-19 globally resulting in more than 1.2 million deaths. Additionally, a growing body of data suggests that some patients with COVID-19, including individuals with mild symptoms, will have a variably prolonged course of recovery including fatigue, cognitive impairment, and cardiopulmonary dysfunction.¹ While treatment options for patients with severe disease requiring hospitalization are now available, with corticosteroids emerging as the treatment of choice for critically ill patients, interventions that can be administered early during the course of infection to prevent disease progression and longer-term complications are urgently needed.²^,3

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Peter S. Kim, MD, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Ln, Bethesda, MD 20892 (peter.kim2@nih.gov).

Published Online: November 11, 2020. doi:10.1001/jama.2020.22813

Conflict of Interest Disclosures: Dr Kim reported serving as the National Institutes of Health (NIH) lead for the ACTIV-2 trial but has no financial relationship with the trial. No other disclosures were reported.

Additional Information: Dr Kim is Director of the Therapeutics Research Program in the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH; Dr Read is Deputy Director of DAIDS; and Dr Fauci is Director, NIAID.

References

Del Rio C , Collins LF , Malani P . Long-term health consequences of COVID-19. JAMA. Published online October 5, 2020. doi:10.1001/jama.2020.19719 PubMed Google Scholar

Prescott HC , Rice TW . Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. JAMA. 2020;324(13):1292-1295. doi:10.1001/jama.2020.16747 PubMed Google Scholar Crossref

Sterne JAC , Murthy S , Diaz JV , et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023 PubMed Google Scholar Crossref

Beigel JH , Tomashek KM , Dodd LE , et al; ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19: final report. N Engl J Med. Published online October 8, 2020. doi:10.1056/NEJMoa2007764 PubMed Google Scholar

The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med. Published online July 17, 2020. doi:10.1056/NEJMoa2021436 Google Scholar

Abella BS , Jolkovsky EL , Biney BT , et al; and the Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med. Published online September 30, 2020. doi:10.1001/jamainternmed.2020.6319 PubMed Google Scholar

Chen P , Nirula A , Heller B , et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. Published online October 28, 2020. doi:10.1056/NEJMoa2029849 PubMed Google Scholar

Regeneron. Regeneron’s REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients [news release]. Published September 29, 2020. Accessed October 15, 2020. https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.